Merck Stock Nearly Doubled Without A Change In Its Revenue Growth
Merck (MRK) stock rose 87% in the past year, despite revenue growth of 4.6% to $66.6B. The increase is attributed to investor optimism about future drugs, including the acquisition of Terns Pharmaceuticals for $5.7B. Merck's pipeline showed progress with FDA approvals and positive trial results, but KEYTRUDA's patent expiration in 2028 poses a risk. The company raised its 2026 revenue guidance to $66.3B-$67.3B, indicating a slight deceleration.
How this was made
The 30-second read
Why it matters
The new guidance and acquisition signal management confidence in future product launches, but the earnings hit from the charge may cause volatility.
Market read
Merck's guidance and acquisition news provide a fresh catalyst for traders, with potential short‑term price movement and longer‑term upside tied to pipeline progress.
What to watch
Pending FDA data for LIPFENDRA (2029) and KEYTRUDA patent expiry in 2028 could constrain long‑term growth.
Background
Merck's stock has surged ~87% YTD despite flat revenue growth, driven by pipeline optimism and a recent guidance update.
Ticker impact
Merck raised its full-year 2026 revenue guidance to $66.3‑$67.3 billion and disclosed a $5.7 billion charge for the Terns Pharma acquisition.
Potential short‑term pullback on earnings hit, followed by upside as pipeline data materialize.
Guidance is modestly higher than prior expectations, but the $5.7 bn charge may depress earnings; investors will watch upcoming FDA decisions.
Market effects
Positive for pharma sector as pipeline milestones emerge, but caution due to pending FDA decisions.
U.S. large‑cap pharma may see modest re‑rating.
Limited to investors tracking major drug developers.
Counterpoint
The guidance lift is modest and the acquisition charge could weigh on earnings, suggesting a short‑term downside.
Key entities
- companyMerck & Co.
U.S. pharmaceutical giant (ticker MRK).
- companyTerns Pharmaceuticals
Acquired by Merck for $5.7 bn, bringing MK‑4208 candidate.
